New Exercise Guidelines, Direct Application: What the 2026 ACSM Update Means If You're on Semaglutide or Tirzepatide
If you're on semaglutide or tirzepatide, you've probably heard some version of the tradeoff: real, effective weight loss, but a meaningful share of what comes off can be muscle, not just fat. The good news is that resistance training and adequate protein are well-established as the two things that actually protect against it — and the American College of Sports Medicine (ACSM), the largest sports medicine organization in the world, just published its first major update to resistance training guidelines in 17 years. It's specific, practical, and it maps almost perfectly onto this exact problem.
Here's what changed, and what it actually means for you.
The Update, in Plain Terms
Published in April 2026 in Medicine & Science in Sports & Exercise, the new ACSM Position Stand synthesized 137 systematic reviews covering more than 30,000 participants — making it the most comprehensive evidence review on resistance training ever assembled. It replaces the 2009 guidelines most trainers and clinicians (myself included) were originally taught.
A few things it clarified or overturned outright:
You don't need to train to failure. The old assumption was that pushing a set until you physically couldn't do another rep was necessary for real gains. The new review found that training to momentary failure doesn't produce better results than stopping a couple reps short — specifically, the recommendation is to stop with about 2-3 reps still left in the tank. This isn't just easier; it's safer, particularly relevant for anyone whose overall energy, recovery capacity, or nutritional intake has shifted — which describes a lot of patients on GLP-1 therapy.
You don't need a gym, specific equipment, or a complicated program. Bodyweight exercises, resistance bands, and home-based routines produce meaningful strength, muscle, and function gains — comparable to traditional gym equipment. This matters enormously for accessibility: if reduced appetite or energy has made a gym membership feel unrealistic, that's no longer a real barrier to protecting your muscle.
Consistency beats complexity. The single biggest gain, according to the review, comes from moving from doing no resistance training to doing any resistance training at all. Perfect programming matters far less than simply showing up regularly.
The Actual Numbers
The guidelines break recommendations out by goal:
For strength: Heavier loads (around 80% of your one-rep max) for 2-3 sets per exercise.
For muscle growth (hypertrophy) — the one that matters most here: A minimum of roughly 10 sets per muscle group per week, with benefit continuing to increase somewhat beyond that. Notably, the review found hypertrophy isn't tied to a specific rep range or load — it's tied to accumulating enough total stimulus over time, so there's real flexibility in how you get there.
For power: Moderate loads (30-70% of max) moved as quickly as possible during the lifting phase — think kettlebell swings, rapid sit-to-stands, or med ball throws.
Frequency: Training all major muscle groups at least twice per week is the primary driver of both hypertrophy and functional strength gains.
Why This Matters Specifically on Semaglutide or Tirzepatide
Here are the real numbers worth knowing: roughly 25-30% of weight lost on these medications can be lean tissue rather than fat, sometimes climbing higher at higher doses. Research shows that resistance training combined with adequate protein (roughly 1.2-1.6 g per kilogram of body weight daily) is what actually preserves — and in some documented cases, even increases — lean mass during treatment.
What the ACSM update adds is the specific prescription to pair with that protein target:
Twice-weekly, full-body resistance sessions hitting all major muscle groups
Roughly 10 sets per muscle group per week, spread across those sessions
Stopping a couple reps short of failure, not grinding every set to exhaustion — genuinely important if your energy or appetite is currently reduced
No gym required — bodyweight and resistance bands are legitimate, evidence-backed tools, not compromises
This is a meaningfully lower barrier to entry than most people assume "real" strength training requires — which matters, because the patients who most need to protect muscle mass during rapid weight loss are often the same patients who feel least equipped to start a serious gym routine.
Putting It Together
If you're currently on semaglutide or tirzepatide, or considering starting either, the combination now has real, specific numbers behind it:
Resistance train at least 2x per week, all major muscle groups
Target ~10 sets per muscle group weekly
Stop sets with 2-3 reps in reserve — no need to push to failure
Pair this with 1.2-1.6 g/kg/day of protein
Bodyweight and bands are legitimate tools if a gym isn't accessible or appealing right now
This is exactly the kind of foundation our Weight Loss Support Essentials collection — protein, creatine, and HMB — was built to support alongside a real training plan, not in place of one.
If you want help building a plan that actually fits your current energy levels and access to equipment, that's a conversation worth having with your provider.
Outlast the Day.
Jeffrey Schnur, FNP-BC Founder & Clinical Director, Apex Coastal Wellness
References
Currier, B.S., D'Souza, A.C., Fiatarone Singh, M.A., et al. American College of Sports Medicine Position Stand: Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews. Medicine & Science in Sports & Exercise, 58(4):851-872, April 2026.
ACSM Unveils Landmark 2026 Resistance Training Guidelines — First Update in 17 Years. American College of Sports Medicine, March 2026.
Wilding, J.P.H., et al. STEP 1 Trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. PMC, 2026.
LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study protocol). PubMed, 2026.
